Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program-Reference-Cited by-同舟云学术

Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program

Published:2024-04-24 Issue:1 Volume:10 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Geukens Tatjana,De Schepper Maxim,Van Den Bogaert Wouter^ORCID,Van Baelen Karen^ORCID,Maetens Marion,Pabba Anirudh,Mahdami Amena^ORCID,Leduc Sophia,Isnaldi Edoardo,Nguyen Ha-Linh^ORCID,Bachir Imane,Hajipirloo Maysam,Zels Gitte,Van Cauwenberge Josephine^ORCID,Borremans Kristien^ORCID,Vandecaveye Vincent,Weynand Birgit,Vermeulen Peter,Leucci Eleonora^ORCID,Baietti Maria Francesca^ORCID,Sflomos George^ORCID,Battista Laura^ORCID,Brisken Cathrin^ORCID,Derksen Patrick W. B.,Koorman Thijs^ORCID,Visser Daan,Scheele Colinda L. G. J.^ORCID,Thommen Daniela S.,Hatse Sigrid,Fendt Sarah-Maria^ORCID,Vanderheyden Evy,Van Brussel Thomas,Schepers Rogier,Boeckx Bram,Lambrechts Diether^ORCID,Marano Giuseppe,Biganzoli Elia^ORCID,Smeets Ann^ORCID,Nevelsteen Ines,Punie Kevin^ORCID,Neven Patrick,Wildiers Hans^ORCID,Richard François^ORCID,Floris Giuseppe^ORCID,Desmedt Christine^ORCID

Abstract

AbstractResearch on metastatic cancer has been hampered by limited sample availability. Here we present the breast cancer post-mortem tissue donation program UPTIDER and show how it enabled sampling of a median of 31 (range: 5-90) metastases and 5-8 liquids per patient from its first 20 patients. In a dedicated experiment, we show the mild impact of increasing time after death on RNA quality, transcriptional profiles and immunohistochemical staining in tumor tissue samples. We show that this impact can be counteracted by organ cooling. We successfully generated ex vivo models from tissue and liquid biopsies from distinct histological subtypes of breast cancer. We anticipate these and future findings of UPTIDER to elucidate mechanisms of disease progression and treatment resistance and to provide tools for the exploration of precision medicine strategies in the metastatic setting.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41523-024-00637-3.pdf

Reference68 articles.

1. Pasha, N. & Turner, N. C. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nat. Cancer 2, 680–692 (2021).

2. Fumagalli, C. & Barberis, M. Breast cancer heterogeneity. Diagnostics 11, 1555 (2021).

3. Schrijver, W. A. M. E. et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J. Natl. Cancer Inst. 110, 568–580 (2018).

4. Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).

5. Angus, L. et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450–1458 (2019).